-$0.46 EPS Expected for Idera Pharmaceuticals Inc (IDRA) This Quarter

Analysts expect that Idera Pharmaceuticals Inc (NASDAQ:IDRA) will report ($0.46) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Idera Pharmaceuticals’ earnings. The highest EPS estimate is ($0.38) and the lowest is ($0.53). Idera Pharmaceuticals posted earnings per share of ($0.80) during the same quarter last year, which indicates a positive year over year growth rate of 42.5%. The company is scheduled to issue its next earnings results on Wednesday, May 8th.

According to Zacks, analysts expect that Idera Pharmaceuticals will report full-year earnings of ($1.89) per share for the current fiscal year, with EPS estimates ranging from ($2.49) to ($1.37). For the next financial year, analysts anticipate that the business will report earnings of ($1.83) per share, with EPS estimates ranging from ($2.58) to ($1.33). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Idera Pharmaceuticals.

Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.12 million. Idera Pharmaceuticals had a negative net margin of 9,045.47% and a negative return on equity of 75.10%.

Several brokerages recently commented on IDRA. Zacks Investment Research downgraded shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine upgraded shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. HC Wainwright dropped their target price on shares of Idera Pharmaceuticals to $14.00 and set a “buy” rating on the stock in a report on Friday, March 8th. Finally, Wedbush set a $7.00 target price on shares of Idera Pharmaceuticals and gave the stock an “outperform” rating in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. Idera Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $16.71.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG raised its stake in shares of Idera Pharmaceuticals by 45.3% in the fourth quarter. Deutsche Bank AG now owns 55,548 shares of the biotechnology company’s stock worth $153,000 after acquiring an additional 17,306 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Idera Pharmaceuticals by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 230,577 shares of the biotechnology company’s stock worth $638,000 after acquiring an additional 8,468 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Idera Pharmaceuticals in the fourth quarter worth about $61,000. Millennium Management LLC raised its stake in shares of Idera Pharmaceuticals by 36.1% in the fourth quarter. Millennium Management LLC now owns 602,639 shares of the biotechnology company’s stock worth $1,669,000 after acquiring an additional 159,916 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Idera Pharmaceuticals in the fourth quarter worth about $39,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Shares of IDRA opened at $2.62 on Friday. Idera Pharmaceuticals has a one year low of $2.25 and a one year high of $17.12.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Featured Story: What Are Treasury Bonds?

Get a free copy of the Zacks research report on Idera Pharmaceuticals (IDRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.